Form 4 for VNDA Vanda Pharmaceuticals Inc.
Accepted 2025-02-26 00:00:00 ET · period of report 2025-02-26 · accession 0000950170-25-027860 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2025-02-26 | 2025-02-26 | VNDA | Polymeropoulos Mihael Hristos | Pres, CEO, Dir, COB | P - Purchase | $4.76 | +10.0K | 2.34M | +0.4% | +$47.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-02-26 | P | A | 5,000 | $4.75 | 2,336,730 | D | — | — | |
| 2 | Common | Common Stock | 2025-02-26 | P | A | 5,000 | $4.78 | 2,341,730 | D | — | — |